Jan 30, 2015 at 17:07 | Source: CNBC-TV18
Prakash Diwan of Altamount Capital Management recommends buying Sun Pharma Advanced Research Company.
Jan 30, 2015 at 12:58 | Source: CNBC-TV18
Gaurav Bissa of LKP Securities is of the view that one can book some profits in Sun Pharma Advanced Research Company.
Jan 28, 2015 at 11:15 | Source: CNBC-TV18
Ranbaxy Laboratories, which will soon become a part of Sun Pharma, will announce its third quarter (October-December) earnings today. Analysts expect the quarter to be a good one due to Diovan generic (is used to treat high blood pressure).
Jan 27, 2015 at 22:22 | Source: CNBC-TV18
Ranbaxy has lost out on its last big drug opportunity in the US market. The US drug regulator has denied the company 180-day exclusivity for the generic version of heart burn drug Nexium. However Archana Shukla reports that Ranbaxy's loss means good times for global rival Teva and Cipla.
Jan 27, 2015 at 14:01 | Source: CNBC-TV18
Pritesh Mehta of IIFL is of the view that one may prefer Cipla, Sun Pharma and Lupin.
Jan 27, 2015 at 12:56 | Source: CNBC-TV18
Watch the interview of Pritesh Mehta of IIFL with Sumaira Abidi & Reema Tendulkar on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Jan 25, 2015 at 16:54 | Source: PTI
Drug major Sun Pharma's top executive Dilip S Shanghvi expects the USD 4-billion Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined entity would be to rebuild the confidence of health regulators.
Jan 23, 2015 at 15:08 | Source: CNBC-TV18
Sharmila Joshi of sharmilajoshi.com is of the view that one may prefer IT, pharma and financial stocks.
Jan 23, 2015 at 11:13 | Source: CNBC-TV18
VK Sharma of HDFC Securities recommends buying Lupin 1500 call and Ranbaxy Labs 700 Call.
Jan 22, 2015 at 16:52 | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com is of the view that Sun pharma, Lupin and Aurobindo Pharma are opportunities.